Literature DB >> 18723609

Long-term observation of 64 patients with roentgenographically occult lung cancer treated with external irradiation and intraluminal irradiation using low-dose-rate iridium.

Nobukazu Fuwa1, Takeshi Kodaira, Hiroyuki Tachibana, Tatsuya Nakamura, Natsuo Tomita, Takashi Daimon.   

Abstract

OBJECTIVE: Therapeutic results of intraluminal irradiation were analyzed in 64 patients with roentgenographically occult lung cancer (ROLC).
METHODS: The subjects were 64 patients who underwent intraluminal irradiation between 1987 and 2003. Radiotherapy was performed by combining external irradiation with intraluminal irradiation using low-dose-rate iridium (four 370-MBq wires) through a catheter with a spacer. The doses of radiation were 0-70 Gy (median value 46 Gy) by external irradiation and 10-60 Gy (median value 29.3 Gy) by intraluminal irradiation.
RESULTS: The therapeutic effect was CR in 63 patients and PR in 1 patient, and local recurrence was observed in a PR case and in seven of the 63 patients who showed CR. The 5-year overall and relapse-free survival rates were 56 (95% CI, 43-69%) and 55% (95% CI, 43-68%), respectively. Fatal pulmonary hemorrhage was observed in one case.
CONCLUSIONS: Considering the facts that ROLC often occurs as multiple cancers and that many patients with ROLC have reduced lung function, radiation therapy by a combination of intraluminal and external irradiation may replace surgery as the first choice for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723609     DOI: 10.1093/jjco/hyn077

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  1 in total

1.  High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers.

Authors:  Mutahir Ali Tunio; Mansoor Rafi; Altaf Hashmi; Rehan Mohsin; Abdul Qayyum; Mujahid Hasan; Amjad Sattar; Muhammad Mubarak
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.